Actively Recruiting
Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen
Led by Chinese PLA General Hospital · Updated on 2026-04-23
50
Participants Needed
1
Research Sites
495 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Chidamide intensified conditioning regimen in patients with Acute B cell Lymphoblast leukemia Underwenting Haploidenticl Peripheral blood Stem Cell Transplantation.
CONDITIONS
Official Title
Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen
Who Can Participate
Eligibility Criteria
You may qualify if you...
- High risk acute B cell lymphoblastic leukemia with indications for allogeneic transplantation
- Have matched sibling donors, 6/10 HLA matched unrelated donors, or haploidentical donors
- Age between 12 and 65 years
- Liver function with ALT and AST 6 2.5 times the upper limit of normal and bilirubin 6 2 times the upper limit of normal
- Renal function with creatinine 6 the upper limit of normal
- No uncontrolled infections, no organ dysfunction, and no severe mental illness
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
- Signed informed consent
You will not qualify if you...
- Pregnant women
- Mental illness or other conditions preventing compliance with the protocol
- Acute lymphoblastic leukemia patients with Philadelphia chromosome positive (Ph positive)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853
Actively Recruiting
Research Team
D
Daihong Liu
CONTACT
L
Liping Dou
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here